What’s New in Psoriasis?
Clearing the Bar for Oral Targeted Therapies
Psoriasis.
Armstrong AW, Blauvelt A, Callis Duffin K, et al. Nat Rev Dis Primers. 2025;11(1):45.
Patient perspectives on psoriatic disease burden: results from the Global Psoriasis and Beyond survey.
Armstrong AW, Bohannan B, Mburu S, et al. Dermatology. 2023;239(4):621-634.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
Armstrong AW, Gooderham M, Warren RB, et al. J Am Acad Dermatol. 2023;88(1):29-39.
Oral icotrokinra for plaque psoriasis in adults and adolescents.
Bissonnette R, Soung J, Hebert AA, et al. N Engl J Med. 2025;393(18):1784-1795.
Psoriasis involving special areas is associated with worse quality of life, depression, and limitations in the ability to participate in social roles and activities.
Blauvelt A, Gondo GC, Bell S, et al. J Psoriasis Psoriatic Arthritis. 2023;8(3):100-106.
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.
Gold LS, Armstrong AW, Bissonnette R, et al. Lancet. 2025;406(10510):1363-1374.
Targeted oral peptide icotrokinra for psoriasis involving high-impact sites.
Gooderham M, Lain E, Bissonnette R, et al. NEJM Evid. 2025;4(12):EVIDoa2500155.
Oral peptide therapeutics as an emerging treatment modality in immune-mediated inflammatory diseases: a narrative review.
Gold LS, Eyerich K, Merola JF, et al. Adv Ther. 2025;42(7):3158-3172.
Evolution of patient perceptions of psoriatic disease: results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey.
Lebwohl M, Langley RG, Paul C, et al. Dermatol Ther (Heidelb). 2022;12(1):61-78.
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
Papp K, Reich K, Leonardi CL, et al. J Am Acad Dermatol. 2015;73(1):37-49.
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
Paul C, Cather J, Gooderham M, et al. Brit J Dermatol. 2015;173(6):1387-1399.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
Strober B, Thaçi D, Sofen H, et al. J Am Acad Dermatol. 2023;88(1):40-45.
Clinician Handout
When to Choose Oral Therapy for Psoriasis: Patient–Clinician Decision Support Tool
Patients with moderate to severe psoriasis who may benefit from systemic therapy will have questions about their options. This guide is designed to support high-quality shared decision-making (SDM) conversations about psoriasis treatment selection.
Clinician and Patient Resources
International Psoriasis Council
A community of researchers and physician experts who share the goal of improving the health and well-being of people with psoriasis worldwide, with a focus on educating health care professionals in psoriasis care management.
National Psoriasis Foundation
The mission of the National Psoriasis Foundation is to drive efforts to cure psoriatic disease and improve the lives of those affected.
From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis.
Armstrong AW, Siegel MP, Bagel J, et al. J Am Acad Dermatol. 2017;76(2):290-298.
Criteria for identifying candidates for systemic psoriasis treatment in the real world: application of the International Psoriasis Council guidelines in patients in North America.
Strober B, Zhong Y, Sima A, et al. J Psoriasis Psoriatic Arthritis. 2024;10(1):22-27.
What’s New in Psoriasis?
Clearing the Bar for Oral Targeted Therapies
| Faculty: | Linda Stein Gold, MD ; Andrew Blauvelt, MD, MBA |
| Release: | 06/17/2026 |
| Expiration: | 06/17/2027 |
